A photo of Brian Turpin.

Member, Division of Oncology

Assistant Professor, UC Department of Pediatrics



Board Certified

My Biography & Research


Brian K. Turpin, DO, completed his undergraduate training at the University of Missouri, graduate medical training at the Kansas City University of Medicine and Biosciences, and pediatric residency and hematology / oncology fellowship at Cincinnati Children’s Hospital Medical Center where he served as co-chief fellow. 

Dr. Turpin’s clinical and academic interests pertain to children and young adults with solid tumors, particularly sarcomas and neuroblastomas, with a research focus on the development of new drugs and clinical trials for patients with relapsed cancer.

Academic Affiliation

Assistant Professor, UC Department of Pediatrics


Cancer and Blood Diseases, Sarcoma, Neuroblastoma, Oncology

My Locations

My Education

DO: Kansas City University of Medicine and Biosciences.

Residency: Pediatrics, Cincinnati Children’s Hospital Medical Center.

Fellowship: Pediatric Hematology / Oncology, Cincinnati Children’s Hospital Medical Center, Cancer and Blood Diseases Institute.

My Publications

Paediatric ganciclovir dosing in extracorporeal membrane oxygenation: Is standard dosing good enough?. Murphy, M; Chamberlain, A; Tang, P; Turpin, B; Danziger-Isakov, L. Journal of Clinical Pharmacy and Therapeutics. 2020; 45:218-220.

Outcomes after bloodstream infection in hospitalized pediatric hematology/oncology and stem cell transplant patients. Dandoy, CE; Kelley, T; Gaur, AH; Nagarajan, R; Demmel, K; Alonso, PB; Guinipero, T; Savelli, S; Hakim, H; Owings, A; et al. Pediatric Blood and Cancer. 2019; 66.

Common Secondary Genomic Variants Associated With Advanced Epithelioid Hemangioendothelioma. Seligson, ND; Awasthi, A; Millis, SZ; Turpin, BK; Meyer, CF; Grand'Maison, A; Liebner, DA; Hays, JL; Chen, JL. JAMA Network Open. 2019; 2:e1912416-e1912416.

Targeting Sporadic and Neurofibromatosis Type 1 (NF1) Related Refractory Malignant Peripheral Nerve Sheath Tumors (MPNST) in a Phase II Study of Everolimus in Combination with Bevacizumab (SARC016). Widemann, BC; Lu, Y; Reinke, D; Okuno, SH; Meyer, CF; Cote, GM; Chugh, R; Milhem, MM; Hirbe, AC; Kim, A; et al. Sarcoma. 2019; 2019:1-8.

Expanding the Spectrum of Pediatric NTRK-rearranged Mesenchymal Tumors. Davis, JL; Lockwood, CM; Stohr, B; Boecking, C; Al-Ibraheemi, A; DuBois, SG; Vargas, SO; Black, JO; Cox, MC; Luquette, M; et al. American Journal of Surgical Pathology. 2019; 43:435-445.

Sentinel lymph node biopsy in head and neck rhabdomyosarcoma. Turpin, B; Pressey, JG; Nagarajan, R; Weiss, BD; Trout, AT; Gelfand, MJ; Pater, L; Vatner, RE; Breneman, JC; Dasgupta, R. Pediatric Blood and Cancer. 2019; 66:e27532-e27532.

Limited detection of human polyomaviruses in Fanconi anemia related squamous cell carcinoma. Toptan, T; Brusadelli, MG; Turpin, B; Witte, DP; Surralles, J; Velleuer, E; Schramm, M; Dietrich, R; Brakenhoff, RH; Moore, PS; et al. PLoS ONE. 2018; 13:e0209235-e0209235.

A study of axitinib, a VEGF receptor tyrosine kinase inhibitor, in children and adolescents with recurrent or refractory solid tumors: A Children's Oncology Group phase 1 and pilot consortium trial (ADVL1315). Geller, JI; Fox, E; Turpin, BK; Goldstein, SL; Liu, X; Minard, CG; Kudgus, RA; Reid, JM; Berg, SL; Weigel, BJ. Cancer. 2018; 124:4548-4555.

The use of neoadjuvant larotrectinib in the management of children with locally advanced TRK fusion sarcomas. DuBois, SG; Laetsch, TW; Federman, N; Turpin, BK; Albert, CM; Nagasubramanian, R; Anderson, ME; Davis, JL; Qamoos, HE; Reynolds, ME; et al. Cancer. 2018; 124:4241-4247.

Pazopanib therapy for desmoid tumors in adolescent and young adult patients. Agresta, L; Kim, H; Turpin, BK; Nagarajan, R; Plemmons, A; Szabo, S; Dasgupta, R; Sorger, JI; Pressey, JG. Pediatric Blood and Cancer. 2018; 65:e26968-e26968.